In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 863-865

  Zhanel, George G ^a,b   Karlowsky, James A ^a,b   Harding, Gary A J ^b   Balko, Tamara V ^a,b   Zelenitsky, Sheryl A ^a   Friesen, Mark ^a   Kabani, Amin ^a,b   Turik, Michael ^c   Hoban, Daryl J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; CANDIDA; CANDIDA PARAPSILOSIS; CANDIDIASIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

EID: 0030896919     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.863     Document Type: Article

References (18)

1. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, W. J. Henderson, and W. J. Marone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States 1980-1989. Am. J. Med. 91(Suppl.3B):86S-89S.
2. Current, W. L., C. J. Boylan, and P. P. Raab. 1993. Anti-Pneumocystis activity of LY303366 and other echinocandin B analogs, abstr. 368, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Debono, M. 1994. The echinocandins: antifungal targets to the fungal cell wall. Exp. Opin. Invest. Drugs 3:821-829.
4. Friesen, M., G. Handing, J. Karlowsky, T. Balko, D. Hoban, A. Kabani, S. Zelenitsky, M. Turik, and G. G. Zhanel. 1996. Antifungal pharmacodynamic activity of the investigational echinocandin LY303366 against fluconazole-sensitive (FLU-S) and fluconazole-resistant (FLU-R) Candida albicans, abstr. F49, p. 108. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371-373.
6. Gooday, G. W. 1995. The potential of novel antifungal drugs for the treatment of disease in the immunocompromised host. Exp. Opin. Invest. Drugs 4:679-691.
7. Gordee, R., J. Farmer, J. Flokowitsch, and P. Haeber. 1993. In vitro antifungal activity of LY303366, a new antifungal agent derived from echinocandin B, abstr. 360, p. 185. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Huang, A., F. Edwards, E. M. Bernard, D. Armstrong, and H. J. Schmitt. 1990. In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 9:697-699.
9. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
10. Lucas, R., K. Desante, B. Hatcher, J. Hemingway, R. Lachno, S. Brooks, and M. Turik. 1996. LY303366 single dose pharmacokinetics and safety in healthy male volunteers, abstr. F50, p. 108. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
12. Pfaller, M. A., S. Messer, and S. Coffman. 1996. In vitro susceptibility of Candida blood stream isolates to a new echinocandin derivative, LY303366, and comparative antifungal agents, abstr. F48, p. 108. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Rennie, R., C. Sand, and S. Smith. 1996. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species, abstr. F45, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Stevens, D. A., M. Martinez, and M. J. Devine. 1996. Antifungal activity of LY303366 (LY), an echinocandin beta glucan synthase inhibitor (GSI), abstr. F46, p. 107. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Vanden Bossche, H., D. W. Warnock, B. Dupont, D. Kerridge, S. Sen Gupta, L. Improvisi, P. Marichal, F. C. Odds, F. Provost, and O. Ronin. 1994. Mechanisms and clinical impact of antifungal resistance. J. Med. Vet. Mycol. 32(Suppl. 1):189-202.
16. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366. activity against systemic aspergillosis and histoplasmosis in murine models, abstr. 364, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366, activity in a murine systemic candidiasis model, abstr. 365, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
18. Zeckner, D., T. Butler, C. Boylan, B. Boyll, P. Watson, and W. Current. 1993. In vitro evaluation of LY-303366 against Candida species clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis, abstr. F98, p. 130. In Program and abstracts of the 33th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.